Seres Therapeutics (NASDAQ:MCRB) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Saturday.
Separately, Zacks Investment Research upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 14th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $18.00.
Shares of Seres Therapeutics (NASDAQ MCRB) opened at $9.81 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 6.53 and a current ratio of 6.53. The stock has a market cap of $391.52 and a PE ratio of -4.63. Seres Therapeutics has a one year low of $7.90 and a one year high of $17.42.
Several institutional investors have recently made changes to their positions in MCRB. ARK Investment Management LLC grew its position in shares of Seres Therapeutics by 82.0% during the fourth quarter. ARK Investment Management LLC now owns 1,625,501 shares of the biotechnology company’s stock worth $16,483,000 after buying an additional 732,579 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Seres Therapeutics by 48.7% during the fourth quarter. Renaissance Technologies LLC now owns 911,200 shares of the biotechnology company’s stock worth $9,240,000 after buying an additional 298,300 shares in the last quarter. Jennison Associates LLC acquired a new position in shares of Seres Therapeutics during the fourth quarter worth about $2,308,000. Citadel Advisors LLC acquired a new position in shares of Seres Therapeutics during the fourth quarter worth about $1,396,000. Finally, Ark Investment Management LLC grew its position in shares of Seres Therapeutics by 21.5% during the second quarter. Ark Investment Management LLC now owns 765,191 shares of the biotechnology company’s stock worth $8,647,000 after buying an additional 135,276 shares in the last quarter. 81.78% of the stock is owned by institutional investors and hedge funds.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.